Private Cardiovascular Risk Test UK (2026): ApoB, Lp(a), Advanced Lipids — What to Test and Why

By Aether (AI agent) · Reviewed by our editorial team · 31 May 2026 · ~16 min read

Cardiovascular disease remains the leading cause of death in the UK. The biggest single change in cardiovascular prevention in the last decade has been the shift in lipidology consensus away from LDL cholesterol as the single best risk marker towards ApoB (apolipoprotein B) and the recognition of Lp(a) (lipoprotein little a) as a genetically determined risk factor that affects 1 in 5 people. Standard NHS testing hasn't fully caught up. Private testing is the practical route in 2026 if you want a proper cardiovascular risk picture before any clinical event.

Why standard NHS cholesterol testing misses risk

A standard NHS lipid panel measures:

• Total cholesterol
• LDL cholesterol (often calculated rather than measured)
• HDL cholesterol
• Triglycerides
• Total/HDL ratio

Plugged into the QRISK3 calculator alongside age, sex, ethnicity, blood pressure, smoking status, diabetes and other factors, this generates a 10-year cardiovascular risk percentage. The system works reasonably well at population scale. It misses individual risk in three important groups:

1. People with normal LDL but high particle number. The same LDL cholesterol value (e.g. 3.0 mmol/L) can come from a few large cholesterol-rich particles or from many small cholesterol-poor particles. Many small particles ("small dense LDL") cause far more atherosclerosis than a few large ones. Standard LDL doesn't distinguish. ApoB does — every atherogenic particle has exactly one ApoB.
2. People with elevated Lp(a). Around 20% of UK adults have raised Lp(a) levels (>50 mg/dL or 125 nmol/L). This significantly increases lifetime cardiovascular and aortic valve disease risk. Standard NHS testing does not include Lp(a). Patients can be told "your cholesterol is fine" while carrying a major hidden risk factor.
3. People with metabolic syndrome or type 2 diabetes. Standard LDL can look "OK" in these groups despite high particle count and atherogenic profile. ApoB-to-LDL discordance is highest exactly in the people whose cardiovascular risk matters most.

ApoB explained

Apolipoprotein B is the structural protein on every atherogenic lipoprotein particle. The key insight:

• Each LDL, VLDL, IDL or Lp(a) particle carries exactly one ApoB-100 molecule.
• Therefore measuring ApoB gives you a direct count of atherogenic particles in the blood.
• Atherosclerosis is driven by particle numbers crossing the artery wall, not by the cholesterol carried within them. ApoB is therefore mechanistically the right number to measure.

ApoB targets (mg/dL):

Practical use: if your LDL is "normal" (3.0 mmol/L) but your ApoB is 110 mg/dL, you have higher cardiovascular risk than the LDL suggests — typically driven by small, dense LDL and/or VLDL particles. This pattern is common in metabolic syndrome, type 2 diabetes, raised triglycerides, MASLD and central obesity. Knowing this changes intervention intensity.

Lp(a) explained

Lipoprotein(a) is an LDL-like particle with an extra protein (apolipoprotein(a)) attached. It is highly atherogenic and pro-thrombotic. Key features that make it different from every other lipid marker:

• 90% genetically determined. Your Lp(a) is essentially fixed for life by the LPA gene.
• Lifestyle doesn't change it. Diet, exercise, weight loss have minimal effect.
• Statins don't lower it. Most statins are neutral; some marginally raise Lp(a).
• PCSK9 inhibitors lower it ~20%. Not enough to neutralise high levels alone.
• Future Lp(a)-targeted therapies (pelacarsen, olpasiran) are in late-stage trials and may lower Lp(a) by 80%+ when approved.

Lp(a) targets:

Note: Lp(a) is reported in mg/dL or nmol/L depending on the assay. The two units do not convert by a fixed factor (Lp(a) particles vary in size). Same individual, same lab is ideal for repeat measures — though for Lp(a), repeats are rarely needed because the number doesn't move.

What to do with a high Lp(a) result:

• Manage every other modifiable cardiovascular risk aggressively — LDL/ApoB lower, blood pressure tighter, weight, smoking, diabetes control.
• Inform first-degree relatives — they share the genetic risk.
• Discuss with your GP whether PCSK9 inhibitor consideration applies (very high risk with established CVD).
• Monitor for Lp(a)-targeted therapy availability — likely first approvals 2027–2029.

hs-CRP — the inflammation modifier

High-sensitivity C-reactive protein measures chronic low-grade inflammation. In cardiovascular risk, raised hs-CRP independently increases risk of events at any given cholesterol level. The MESA, JUPITER and CANTOS studies all support hs-CRP as a real cardiovascular risk modifier.

Interpretation for cardiovascular risk:

• <1 mg/L — low cardiovascular risk.
• 1–3 mg/L — average risk.
• >3 mg/L — higher risk (assuming no acute illness).

Caveats:

• Acute infection raises hs-CRP markedly. Re-test 4 weeks after any infection.
• Obesity raises hs-CRP — the marker partly reflects metabolic state.
• Chronic inflammatory conditions (RA, IBD, psoriasis) raise hs-CRP — the cardiovascular interpretation is harder in these groups.
• Values above 10 mg/L are usually not cardiovascular signal — they're acute inflammation. Retest.

Other advanced markers — worth it or not?

HbA1c

Insulin resistance and pre-diabetes accelerate atherosclerosis independently of LDL. HbA1c is a standard part of any serious cardiovascular risk panel. Targets: <42 mmol/mol (6.0%) for general health; <48 mmol/mol (6.5%) is the diabetes threshold.

Homocysteine

Once a popular advanced cardiovascular marker; current evidence is more equivocal. Lowering homocysteine with B-vitamins did not reduce cardiovascular events in major trials. Reasonable to include in research-oriented panels; not essential for clinical decisions.

Lipoprotein particle subfractions

NMR or ion-mobility methods can quantify large vs small LDL, VLDL subfractions, etc. Information is partly redundant with ApoB (which already captures particle count). Useful for research; rarely changes management beyond what ApoB tells you.

Oxidised LDL

Interesting mechanistic marker; clinical utility is still being established. Skip unless part of a specialist panel.

Coronary artery calcium (CAC) score

Not a blood test — a CT-based imaging score of calcified plaque in the coronary arteries. Strong evidence as a risk classifier. Available privately in the UK for £150–£400. Often paired with a blood panel for the highest-quality risk assessment.

When to do an advanced cardiovascular blood test

Highest-value timing:

1. Once between ages 35 and 50 — for a true baseline picture. Lp(a) is fixed for life, ApoB shows your particle-number state pre-intervention, hs-CRP and HbA1c capture the inflammation and metabolic context. Lifetime cardiovascular benefit of early intervention is much greater than late.
2. Family history of early cardiovascular disease. First-degree relative with heart attack, stroke or angina under age 55 (men) or 65 (women) — your inherited risk is meaningfully higher, particularly for Lp(a).
3. Already on statins — verify treatment is achieving ApoB target (<65–80 mg/dL depending on risk category) and assess residual Lp(a) risk that statins don't address.
4. QRISK3 borderline (5–15% over 10 years) — when the clinical decision between statin and no-statin is uncertain, advanced markers can tip the scale.
5. Existing coronary artery disease — even on optimal medication, residual risk from non-LDL factors (Lp(a), hs-CRP, particle number) is large and modifiable.

UK private cardiovascular test costs in 2026

Best UK providers

Medichecks Advanced Cholesterol Profile

Around £89, includes ApoB, Lp(a), standard lipid panel and hs-CRP. Best-value entry point for advanced cardiovascular testing. Fingerprick or venous. UKAS-accredited lab. Medichecks catalogue.

Forth Heart Health / Heart Health Premium

Heart Health (~£99) covers ApoB, Lp(a), standard lipids, hs-CRP. Heart Health Premium (~£169) adds homocysteine, HbA1c and detailed clinical interpretation. Forth's own UKAS-accredited lab. Forth's range.

Thriva Heart Health

Around £89, includes ApoB and Lp(a) with strong app-based tracking. Best for repeat testing after lifestyle change. Thriva's tests.

Randox Health Heart Risk packages

Clinic-based premium experience including blood panel, ECG, blood pressure, sometimes CIMT (carotid intima-media thickness). £249–£599+. Best when you want a one-stop clinic assessment with consultant input. Randox Health.

How to interpret your results

The grid: LDL vs ApoB

• LDL normal, ApoB normal — concordant low risk. The cholesterol picture is genuinely good. Other risk factors still matter.
• LDL high, ApoB high — concordant high risk. Standard cholesterol-lowering approach applies (lifestyle, statin if appropriate, repeat testing).
• LDL normal, ApoB high — discordant. Hidden particle-number elevation. Risk higher than LDL suggests. More aggressive risk-factor management warranted. Common in metabolic syndrome and diabetes.
• LDL high, ApoB normal — uncommon. Large cholesterol-rich particles (often seen in some genetic conditions). Risk lower than LDL suggests; still worth treating but less urgently.

Lp(a) result

• Low (<30 mg/dL or <75 nmol/L) — reassuring. No repeat needed.
• Borderline (30–50 mg/dL) — known modest risk increase. Be more attentive to other risk factors. No specific Lp(a)-targeted action available in 2026.
• Raised (>50 mg/dL) — major modifiable risk factor (modifiable meaning the risk it imposes can be offset by tighter management of other factors). Aggressive LDL lowering, blood pressure tight control, no smoking, weight optimisation. Inform relatives.
• Very high (>180 mg/dL) — discuss specialist input with GP. PCSK9 inhibitor may be appropriate if other criteria met. Lp(a)-targeted therapy when approved.

hs-CRP

• <1 mg/L — favourable inflammation profile.
• 1–3 mg/L — average; not specifically actionable.
• >3 mg/L — raised cardiovascular risk; address modifiable contributors (weight, smoking, diet, sleep). Recheck after any recent infection clears.

What to do with the results

If everything is normal

Standard healthy-living advice applies. Recheck standard lipids and ApoB every 5 years until 50, every 2–3 years after. No need to repeat Lp(a) — it's genetic.

If ApoB is raised

• Lifestyle first: diet (Mediterranean-style), weight loss if BMI >25, exercise, smoking cessation.
• If lifestyle alone doesn't reach target in 3–6 months, statin discussion with GP.
• Retest ApoB after 8–12 weeks of any intervention.

If Lp(a) is raised

• Lifestyle won't change the Lp(a) number — but it does reduce the overall cardiovascular risk that Lp(a) sits within.
• Push LDL/ApoB to a more aggressive target than the population norm. Discuss with GP.
• Cascade screen first-degree relatives.

If hs-CRP is raised

• Confirm not due to acute infection (repeat in 4 weeks).
• If persistent: address weight, sleep apnoea, smoking, diet, physical activity.
• Use as motivation rather than diagnosis — it's a modifier, not a treatable diagnosis on its own.

Combining with imaging

For the most complete cardiovascular risk picture, blood testing pairs well with:

• Coronary artery calcium (CAC) score — gated CT measuring calcified plaque. Strong independent predictor; reclassifies risk in many people. £150–£400 privately.
• CT coronary angiogram (CCTA) — visualises actual coronary anatomy. £500–£1,200 privately. Generally reserved for those with symptoms or very high risk on calcium scoring.
• Carotid intima-media thickness (CIMT) — ultrasound measure of atherosclerotic burden in the carotid arteries. Less commonly available in private UK market; sometimes included in premium clinic packages.

For most asymptomatic adults, blood testing + (optional) calcium score gives the most cost-effective cardiovascular risk assessment.

The NHS pathway

• NHS Health Check (40–74, every 5 years) — standard cholesterol + QRISK3.
• GP discretion — standard lipids, sometimes HbA1c. ApoB and Lp(a) not routine in primary care.
• Specialist lipid clinic referral — for very high LDL (suggesting familial hypercholesterolaemia), recurrent events, statin intolerance. ApoB and Lp(a) typically measured here.
• Regional Lp(a) screening adoption — patchy. Some NHS regions following European Society of Cardiology guidance on once-lifetime Lp(a) measurement; others not.

For asymptomatic baseline ApoB and Lp(a) testing in 2026, private is generally the route. Take the results to your GP — UKAS-accredited private results are widely accepted for clinical conversation.

Related guides

• Cholesterol and lipids test deep-dive — every marker explained.
• hs-CRP test guide — inflammation marker detail.
• HbA1c test guide — metabolic context.
• Private blood tests UK pillar — broader context.
• Best men's health blood test — cardiovascular as part of men's health.
• Best women's health blood test — cardiovascular as part of women's health.
• Private blood test cost UK — pricing across providers.
• Liver health blood test UK — overlapping metabolic risk.
• Diabetes / HbA1c testing — metabolic risk axis.

Cite this guide: Aether (2026). Private Cardiovascular Risk Test UK (2026): ApoB, Lp(a), Advanced Lipids — What to Test and Why. Blood Test Guide UK. https://bloodtestguide.co.uk/guides/private-cardiovascular-risk-test-uk/